372 related articles for article (PubMed ID: 26811494)
1. Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites.
Lim B; Kim C; Kim JH; Kwon WS; Lee WS; Kim JM; Park JY; Kim HS; Park KH; Kim TS; Park JL; Chung HC; Rha SY; Kim SY
Oncotarget; 2016 Feb; 7(7):8055-66. PubMed ID: 26811494
[TBL] [Abstract][Full Text] [Related]
2. Malignant ascites-derived exosomes promote peritoneal tumor cell dissemination and reveal a distinct miRNA signature in advanced gastric cancer.
Hu Y; Qi C; Liu X; Zhang C; Gao J; Wu Y; Yang J; Zhao Q; Li J; Wang X; Shen L
Cancer Lett; 2019 Aug; 457():142-150. PubMed ID: 31075288
[TBL] [Abstract][Full Text] [Related]
3. Whole-exome sequencing to identify somatic mutations in peritoneal metastatic gastric adenocarcinoma: A preliminary study.
Liu H; Li F; Zhu Y; Li T; Huang H; Lin T; Hu Y; Qi X; Yu J; Li G
Oncotarget; 2016 Jul; 7(28):43894-43906. PubMed ID: 27270314
[TBL] [Abstract][Full Text] [Related]
4. Lysophosphatidic Acid is a Biomarker for Peritoneal Carcinomatosis of Gastric Cancer and Correlates with Poor Prognosis.
Zeng R; Li B; Huang J; Zhong M; Li L; Duan C; Zeng S; Huang J; Liu W; Lu J; Tang Y; Zhou L; Liu Y; Li J; He Z; Wang Q; Dai Y
Genet Test Mol Biomarkers; 2017 Nov; 21(11):641-648. PubMed ID: 28910191
[TBL] [Abstract][Full Text] [Related]
5. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
Park C; Ha SY; Kim ST; Kim HC; Heo JS; Park YS; Lauwers G; Lee J; Kim KM
Oncotarget; 2016 Jan; 7(4):4024-35. PubMed ID: 26684240
[TBL] [Abstract][Full Text] [Related]
6. Comparative proteomic analysis of human malignant ascitic fluids for the development of gastric cancer biomarkers.
Jin J; Son M; Kim H; Kim H; Kong SH; Kim HK; Kim Y; Han D
Clin Biochem; 2018 Jun; 56():55-61. PubMed ID: 29654727
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of minimal ascites of indeterminate nature in gastric adenocarcinoma without peritoneal carcinomatosis: long-term follow-up study.
Lee H; Hwang HS; Chang DK; Choi D; Rhee PL; Kim JJ; Rhee JC
Hepatogastroenterology; 2011; 58(105):137-42. PubMed ID: 21510301
[TBL] [Abstract][Full Text] [Related]
8. Genomic alterations in BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer.
Park H; Cho SY; Kim H; Na D; Han JY; Chae J; Park C; Park OK; Min S; Kang J; Choi B; Min J; Kwon JY; Suh YS; Kong SH; Lee HJ; Liu ET; Kim JI; Kim S; Yang HK; Lee C
Proc Natl Acad Sci U S A; 2015 Oct; 112(40):12492-7. PubMed ID: 26401016
[TBL] [Abstract][Full Text] [Related]
9. The EGFR ligands amphiregulin and heparin-binding egf-like growth factor promote peritoneal carcinomatosis in CXCR4-expressing gastric cancer.
Yasumoto K; Yamada T; Kawashima A; Wang W; Li Q; Donev IS; Tacheuchi S; Mouri H; Yamashita K; Ohtsubo K; Yano S
Clin Cancer Res; 2011 Jun; 17(11):3619-30. PubMed ID: 21482691
[TBL] [Abstract][Full Text] [Related]
10. Computed tomographic characteristics for patients with unresectable gastric cancer harboring low-volume peritoneal carcinomatosis.
Guo JC; Chang CC; Yang CY; Liao BC; Liau JY; Chang CH; Yeh KH
Med Oncol; 2017 Aug; 34(8):143. PubMed ID: 28726044
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of CT-defined minimal ascites in patients with gastric cancer.
Chang DK; Kim JW; Kim BK; Lee KL; Song CS; Han JK; Song IS
World J Gastroenterol; 2005 Nov; 11(42):6587-92. PubMed ID: 16425349
[TBL] [Abstract][Full Text] [Related]
12. Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer.
Yasumoto K; Koizumi K; Kawashima A; Saitoh Y; Arita Y; Shinohara K; Minami T; Nakayama T; Sakurai H; Takahashi Y; Yoshie O; Saiki I
Cancer Res; 2006 Feb; 66(4):2181-7. PubMed ID: 16489019
[TBL] [Abstract][Full Text] [Related]
13. Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites.
Kitayama J; Ishigami H; Yamaguchi H; Yamashita H; Emoto S; Kaisaki S; Watanabe T
Ann Surg Oncol; 2014 Feb; 21(2):539-46. PubMed ID: 23975319
[TBL] [Abstract][Full Text] [Related]
14. Significance of SYT8 For the Detection, Prediction, and Treatment of Peritoneal Metastasis From Gastric Cancer.
Kanda M; Shimizu D; Tanaka H; Tanaka C; Kobayashi D; Hayashi M; Iwata N; Niwa Y; Yamada S; Fujii T; Sugimoto H; Murotani K; Fujiwara M; Kodera Y
Ann Surg; 2018 Mar; 267(3):495-503. PubMed ID: 28026832
[TBL] [Abstract][Full Text] [Related]
15. Tumor-promoting macrophages prevail in malignant ascites of advanced gastric cancer.
Eum HH; Kwon M; Ryu D; Jo A; Chung W; Kim N; Hong Y; Son DS; Kim ST; Lee J; Lee HO; Park WY
Exp Mol Med; 2020 Dec; 52(12):1976-1988. PubMed ID: 33277616
[TBL] [Abstract][Full Text] [Related]
16. Whole genome and transcriptome sequencing of matched primary and peritoneal metastatic gastric carcinoma.
Zhang J; Huang JY; Chen YN; Yuan F; Zhang H; Yan FH; Wang MJ; Wang G; Su M; Lu G; Huang Y; Dai H; Ji J; Zhang J; Zhang JN; Jiang YN; Chen SJ; Zhu ZG; Yu YY
Sci Rep; 2015 Sep; 5():13750. PubMed ID: 26330360
[TBL] [Abstract][Full Text] [Related]
17. Genomic profile of pseudomyxoma peritonei analyzed using next-generation sequencing and immunohistochemistry.
Nummela P; Saarinen L; Thiel A; Järvinen P; Lehtonen R; Lepistö A; Järvinen H; Aaltonen LA; Hautaniemi S; Ristimäki A
Int J Cancer; 2015 Mar; 136(5):E282-9. PubMed ID: 25274248
[TBL] [Abstract][Full Text] [Related]
18. KAP1 is associated with peritoneal carcinomatosis in gastric cancer.
Yokoe T; Toiyama Y; Okugawa Y; Tanaka K; Ohi M; Inoue Y; Mohri Y; Miki C; Kusunoki M
Ann Surg Oncol; 2010 Mar; 17(3):821-8. PubMed ID: 19898899
[TBL] [Abstract][Full Text] [Related]
19. Pathway of peritoneal carcinomatosis maybe hematogenous metastasis rather than peritoneal seeding.
Ge W; Chen G; Fan XS
Oncotarget; 2017 Jun; 8(25):41549-41554. PubMed ID: 28099909
[TBL] [Abstract][Full Text] [Related]
20. Cell-free and concentrated ascites reinfusion therapy (CART) for management of massive malignant ascites in gastric cancer patients with peritoneal metastasis treated with intravenous and intraperitoneal paclitaxel with oral S-1.
Yamaguchi H; Kitayama J; Emoto S; Ishigami H; Ito T; Hanafusa N; Watanabe T
Eur J Surg Oncol; 2015 Jul; 41(7):875-80. PubMed ID: 25986856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
